Shanghai Pharmaceuticals Holding Co., Ltd
Clinical trials sponsored by Shanghai Pharmaceuticals Holding Co., Ltd, explained in plain language.
A Chinese pharmaceutical company involved in R&D, manufacturing, and distribution.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced melanoma: T3011 trial launches Results expected Sep 2026 (estimated)
- New hope for advanced breast cancer: drug combo targets resistant tumors Results expected Dec 2026 (estimated)
- New stroke drug shows promise in Mid-Stage trial Results expected Dec 2026 (estimated)
- New drug B001 tested for rare autoimmune disease Results expected Dec 2026 (estimated)
- New pill shows promise for Hard-to-Treat HER2 cancers Results expected Dec 2026 (estimated)